Patent · US Active

Method for treating and prognosing cancer

US10697965B2 · kind B2 · utility

1Cited by

0References

5Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
UNIVERSITE DE NANTES · FR
UNIVERSITE D'ANGERS · FR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

Pierre-Francois Cartron · Nantes, FR
Mathilde Cheray · Stockholm, SE
Francois Valette · Nantes, FR

Key dates

Filing date	Mar 1, 2016
Grant date	Jun 30, 2020
Priority date	—
Expiry date	Mar 1, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3γ in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3γ antagonist or a compound which is a DNMT3A/ISGF3γ gene expression inhibitor for use in the treatment and prevention of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.